Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Prediabetes, Prediabetes (Insulin Resist...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Dietary Supplement: Peanuts — 43 g of peanut butter (1 snack cup) 3 x/week, 42 g of dry roasted peanuts (1/3 of a cup) 3x/week, or 56 g of peanut flour 1x/week for 6 months.

Primary Outcomes

  • Blood Glucose (Baseline, 3 months, and 6 months)
  • Glycosylated hemoglobin (Baseline, 3 months, and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-06
Completion: 2027-09
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgia State University
Collaborators: United States Department of Agriculture (USDA), The Peanut Institute
Principal Investigators:
  • Rafaela G Feresin, PhD (PRINCIPAL_INVESTIGATOR) - Georgia State University
Contact Information
Study Contact:
Rafaela G Feresin, PhD
404-413-1233
peanuts@gsu.edu
Rafaela G Feresin, PhD
404-413-1233
peanuts@gsu.edu
Georgia State University
Rafaela G Feresin, PhD
Georgia State University
Interventions
  • Dietary Supplement: Peanuts — 43 g of peanut butter (1 snack cup) 3 x/week, 42 g of dry roasted peanuts (1/3 of a cup) 3x/week, or 56 g of peanut flour 1x/week for 6 months.
Study Locations (1 sites)
Georgia State University, Atlanta, Georgia 30303 United States
Eligibility Criteria
Inclusion Criteria: * men and women * 20-59 years of age * BMI: 24.5 - 35.5 kg/m\^2 * Prediabetes (fasting blood glucose levels 100-125 mg/dL and/or HbA1c between 5.7-6.4%) * Ability to give consent Exclusion Criteria: * Allergies to peanuts and peanut products * Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs * Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury * Smoking * Consumes greater than 2 alcoholic beverages per day * Consumes antioxidant, probiotic, and prebiotic supplements * Pregnant or Lactating * Actively participating in a weight loss program MRI Exclusion Criteria: * Certain neurological disorders (e.g., uncontrolled seizure disorders) * Braces on their teeth, a cardiac pacemaker; hearing aid; other metal in the body or eyes (which may include certain metallic-embedded tattoos), including but not limited to pins, screws, shrapnel, plates, dentures or other metal objects
Conditions Painful Diabetic Neuropathy (PDN), Perip...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical trial is to determine whether targeted nutritional changes can improve symptoms of painful diabetic neuropathy. Impaired blood flow to peripheral nerves-resulting in reduced oxygen delivery and subsequent nerve injury-is a well-established contributor to neuropathy. Prior studies have shown that a whole-food, plant-based diet without added oils can improve or even reverse arterial disease, suggesting a potential mechanism for enhancing nerve perfusion and function. This study is a randomized controlled trial comparing a whole-food, plant-based diet with standard pharmacologic management for painful diabetic neuropathy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Diet — Plant-based diet
  • Other: Medical management — Medication optimization

Primary Outcomes

  • Numerical Rating Scale (NRS) (2 months)
  • Average pain on Numerical Rating Scale (NRS) (2 months)
  • ≥50% improvement of pain (2 months)
  • ≥75% improvement of pain (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-23
Completion: 2028-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AdventHealth
Contact Information
Study Contact:
William J Beckworth, MD
828-654-8546
william.beckworth.md@adventhealth.com
Mary Stanford, Clinical Research Coordinator
828-654-8546
mary.stanford@adventhealth.com
Mary Stanford, Clinical Research Coordinator
828-654-8546
mary.stanford@adventhealth.com
AdventHealth Hendersonville
Interventions
  • Other: Diet — Plant-based diet
  • Other: Medical management — Medication optimization
Study Locations (1 sites)
AdventHealth Hendersonville, Hendersonville, North Carolina 28759 United States
Eligibility Criteria
Inclusion Criteria: * Definitive diagnosis of type II diabetes mellitus (HgA1c ≥ 6.5) or pre-diabetes (HgA1c 5.7-6.4) * objective documentation of peripheral neuropathy on EMG/NCS testing defined as a sural-to-radial amplitude ratio of 0.21 or less * presence of painful neuropathy in addition to decreased sensation * with pain rated ≥4/10 on a 0-10 numerical rating scale (NRS) * age 18 years or older * ability to provide informed consent * ability to attend follow-up visits. Exclusion Criteria: * Potential causes of neuropathy other than type II diabetes mellitus (as listed below) * type I diabetes * vitamin B12 deficiency * folate deficiency * thyroid dysfunction, * other nutritional deficiencies * autoimmune disorders * inflammatory disorders * HIV/AIDS * exposure to metals or toxins * multiple myeloma, * moderate to severe lumbar stenosis with neurogenic claudication
Conditions Type 2 Diabetes
Phase EARLY_PHASE1
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Metformin — Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .

Primary Outcomes

  • Acceptability of Higher Metformin Dose measured with the Acceptability of Intervention Measure (AIM) (Measured at 3 months)
  • Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM) (Measured at 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-04-25
Completion: 2026-12-31
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: true
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Shylaja Srinivasan, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Avani A Narayan, MS
628-224-8364
avani.narayan@ucsf.edu
Laura A. Dapkus Humphries, NCPT
628-224-8364
laura.dapkus@ucsf.edu
Shylaja Srinivasan, MD
415-353-9084
Shylaja.Srinivasan@ucsf.edu
UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic
Interventions
  • Drug: Metformin — Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
Study Locations (2 sites)
UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic, Oakland, California 94609 United States
UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric Diabetes, San Francisco, California 94158 United States
Eligibility Criteria
Inclusion Criteria: * Age 10-21 years * Provider diagnosis of T2D * Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose) * ≥ 1 month from T2D diagnosis * Taking regular metformin (not extended-release formula) * Ability to wear CGM for a total of 6 weeks while in the study. * English or Spanish speakers. * Willing to abide by recommendations and study procedures. * Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF. * Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8). * Known history of ongoing renal or hepatic disease. * Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.
Conditions Insulin Dependent Diabetes, Diabetes (DM...
Phase NA
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin. This study will learn if a three-stage CGM integration program ("intervention") that includes sessions focused on CGM technology skills, data skills, and lifestyle skills impacts CGM wear-time, glycemic metrics, and participant-reported outcomes, compared to two standard CGM training approaches ("comparators"). Following a screening visit and baseline data collection, participants will be randomized to either the intervention or one of the two comparator arms for 6 weeks. The intervention involves three educational sessions over 4 weeks. The first session will be in-person and subsequent sessions will be virtual. Participants in the intervention may receive 1-2 additional individualized training sessions to review CGM skills. The first comparator (Comparator 1) will receive a one-time clinic-based CGM training. The second comparator (Comparator 2) will be provided with a comprehensive informational pamphlet about CGM. All participants will complete outcomes data collection at 6 weeks. The study will also explore participant experiences through a series of semi-structured interviews with a subset of purposively selected participants and their care partners to identify opportunities for scaling the intervention to a broader population. An extension phase of the study will evaluate long-term CGM use and associated outcomes 3- and 6-months post-intervention. Lastly, we will run an additional small sub-study where consented care partners of participants will attend the intervention or comparator sessions alongside the study participant and provide care partner-specific data.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Three-stage CGM integration program — Participants (and their consented care partner, if applicable) who are randomized to the intervention group will attend three closed group sessions over four weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be hybrid and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be hybrid and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.
  • Behavioral: One-time clinic-based CGM training — Participants (and their consented care partner, if applicable) randomized to the one-time clinic-based CGM training group (Comparator A) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.
  • Behavioral: Self-directed CGM training — Participants randomized to the self-directed CGM training (Comparator B) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Consented care partners will not be directly involved, as there is no session visit to attend.

Primary Outcomes

  • CGM Wear Time (Over 6 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-11
Completion: 2028-06
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: American Diabetes Association
Principal Investigators:
  • Anna Kahkoska, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Marcy Menard, MS, RD, LDN, CDCES
919-843-9977
mmenard@unc.edu
Angela Fruik, MPH, RD, LDN
919-962-6348
angela.fruik@unc.edu
Marcy Menard, MS, RD, LDN, CDCES
919-843-9977
mmenard@unc.edu
University of North Carolina at Chapel Hill
Interventions
  • Behavioral: Three-stage CGM integration program — Participants (and their consented care partner, if applicable) who are randomized to the intervention group will attend three closed group sessions over four weeks. Session 1 (Day 1) will be held in-person, where participants will receive technical training related to CGM sensor insertion, transmitter pairing, and receiver operation. Session 2 (Day 14) will be hybrid and will consist of training in how to read and understand CGM data, customize target ranges, alerts, and alarms, export and review historical data, and share CGM data with care partners. Session 3 (Day 28) will also be hybrid and will consist of training in strategies to utilize CGM for improved safety and quality of life. Between each session, participants will be remotely assessed for CGM use and glucose trends. Based on these remote assessments, participants may receive 1-2 additional individualized training sessions to review CGM technical skills, as well as data and self-management strategies associated with CGM use.
  • Behavioral: One-time clinic-based CGM training — Participants (and their consented care partner, if applicable) randomized to the one-time clinic-based CGM training group (Comparator A) will complete a one-hour visit with a clinic-based educator on Day 1 of the trial. This group will be provided with basic CGM training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period.
  • Behavioral: Self-directed CGM training — Participants randomized to the self-directed CGM training (Comparator B) will be provided with a comprehensive informational pamphlet about CGM on Day 1 of the trial. They will also be provided with a list of online resources for CGM self-training and be advised to follow up with their usual diabetes care team as needed for questions or issues throughout the 6-week trial period. Consented care partners will not be directly involved, as there is no session visit to attend.
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Participant Inclusion Criteria: * Adults 65 years and older at time of consent * Actively receiving care at a UNC Health or UNC Physicians Network clinic (defined as 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics within the past 365 days). Locality for care is defined as receiving care within a 90-mile radius of UNC Main Hospital on Manning Drive in Chapel Hill, NC. * Using any insulin at least once daily * No continuous glucose monitor (CGM) use within the previous 365 days * Willing to use a smartphone to access glucose readings using CGM phone app * Fluent in English Participant Exclusion Criteria: * Clinical diagnosis of dementia, assessed through chart review and self-report on screening visit (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable) * Currently receiving dialysis, assessed through chart review and self-report on screening visit * Extreme visual or hearing impairment that would impair ability to use real-time CGM or attend and participate in an in-person or virtual group intervention session, assessed at screening visit * The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \<1 year, assessed at screening visit * Unavailable for 6-week study duration (such as planned surgery or procedure, planned vacation, etc.) or unwilling to comply with study procedures * Not fluent in English * Unable to consent to recording of sessions Care Partner Inclusion Criteria: * Live in the same household as the study participant * Age 18 years or older * Fluent in English * Be willing to attend sessions alongside the study participant and learn how they can better support their partner participant to manage diabetes * Consent to recording of sessions
Conditions Type 1 Diabetes
Phase EARLY_PHASE1
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The meal tests are followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide (Rybelsus®) — 7 mg single dose of Rybelsus® by mouth once before each MMTT
  • Drug: Placebo — placebo capsule or tablet once before each MMTT.

Primary Outcomes

  • Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study (During the MMTT in which the participant is randomly selected to receive semaglutide (Rybelsus®), glucose level will be checked at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 minutes)
  • Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study (Based on the glucose and insulin readings obtained at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 min and calculated approximately 1 month following completion of the MMTT once insulin levels in plasma are resulted.)
  • Determine the impact of GLP-1Ra on endothelial function in a pilot study (During the last 30 minutes of each MMTT, between the 210 and 240 timepoints)
  • Determine how much GLP-1Ra monotherapy therapy changes the disposition index (DI) in a pilot study of early stage 3 T1DM. (During the MMTT in which the participant is randomly selected to receive semaglutide (Rybelsus®), glucose level will be checked at timepoints -30, -15, 0, 10, 20, 30, 60, 90, 120, 150, 180, and 240 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-06-12
Completion: 2027-03
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact Information
Study Contact:
Daniel J Moore, MD, PhD
(615) 322- 7427
metabolism@vumc.org
Wendi Welch, CCRP
metabolism@vumc.org
Daniel J Moore, MD, PhD
(615) 322- 7427
metabolism@vumc.org
Vanderbilt University Medical Center
Interventions
  • Drug: Semaglutide (Rybelsus®) — 7 mg single dose of Rybelsus® by mouth once before each MMTT
  • Drug: Placebo — placebo capsule or tablet once before each MMTT.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Aims 1-3: Stage 2 T1DM with TZIELD® and GLP-1Ra Inclusion Criteria: * Age: 12-50 years * BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric) * Stage 2 T1DM (i.e., ≥ 2 islet auto-antibodies and: * fasting glucose ≥ 100 mg/dL and \< 126 mg/dL OR * 2-hr OGTT /MMTT ≥ 140 mg/dL and \< 200 mg/dL OR * During an OGTT having a glucose of \> 199 mg/dL at 30, 60, or 90 minutes) Exclusion Criteria: * Comorbidities: * SBP \> 140 mmHg and DBP \> 100 mmHg * eGFR by MDRD equation of \< 60 mL/min/1.73m2 * AST or ALT \> 2.5 times ULN * Family history of medullary thyroid carcinoma * Diagnosis of pancreatitis or gastroparesis within the past 3 years * Medications: Any diabetes medication, any antioxidant vitamin supplement (\<2 weeks before a study), any systemic glucocorticoid, antipsychotic, atenolol, metoprolol, propranolol, niacin, any thiazide diuretic, any OCP with \> 35 mcg ethinyl estradiol, growth hormone, any immunosuppressant, antihypertensive, any antihyperlipidemic * Other: pregnancy, peri- or post-menopausal women, active smoker Aim 4: Early Stage 3 T1DM with GLP-1Ra Monotherapy Inclusion Criteria * Age: 12-50 years * BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric) * Early stage 3 T1DM with either * HbA1c 6.5% to 8.0% at diagnosis OR * HbA1c 5.7% to 6.4% with oral glucose test meeting ADA criteria for stage 3 T1DM within the past three months prior to or during screening visit * Time of stage 3 diagnosis: within eight weeks of first study visit Exclusion Criteria * DKA history: history of diabetic ketoacidosis requiring hospital admission * Comorbidities: * Family history of medullary thyroid carcinoma * Diagnosis of pancreatitis or gastroparesis within the past 3 years * Medications: Any diabetes medication, any antioxidant vitamin supplement (\<2 weeks before a study), any systemic glucocorticoid, antipsychotic, atenolol, metoprolol, propranolol, niacin, any thiazide diuretic, any OCP with \> 35 mcg ethinyl estradiol, growth hormone, any immunosuppressant, antihypertensive, any antihyperlipidemic * Other: pregnancy, peri- or post-menopausal women, active smoker
Conditions Diabetes Type 2
Phase Not Applicable
Enrollment 154
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Glycated Hemoglobin (HbA1c) (Baseline, Week 12, and Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-09-23
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 154 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact Information
Study Contact:
Paloma Almeda Valdés, MD, PhD
525554870900
paloma.almedav@incmnsz.mx
Interventions
N/A
Study Locations (1 sites)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City 14080 Mexico
Eligibility Criteria
Inclusion Criteria: * Male and female participants * Aged 18 to 65 years * Diagnosis of type 2 diabetes * Estimated glomerular filtration rate (eGFR) \>60 mL/min * Glycated hemoglobin (HbA1c) ≤8% * Participants who are treatment-naïve, receiving metformin monotherapy, or receiving dual glucose-lowering therapy * Participants who agree to take part in the study Exclusion Criteria: * Participants receiving treatment with three glucose-lowering medications * Participants receiving insulin therapy * Pregnancy * Breastfeeding * Chronic conditions such as HIV infection, cancer, or rheumatologic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) * Body mass index (BMI) ≥45 kg/m² * Concurrent participation in another research study
Conditions Diabetes Mellitus Type 2, Childhood-Onse...
Phase Not Applicable
Enrollment 3600
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Type 2 diabetes (Through study completion, an average of 2.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2028-01-31
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 3600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: George Washington University
Contact Information
Study Contact:
Barbara Braffett, PhD
3018819260
braffett@bsc.gwu.edu
Brian Burke, MS
3018819260
bburke@bsc.gwu.edu
Laura Lee Goree
205-934-4386
discovery@uab.edu
University of Alabama at Birmingham
Interventions
N/A
Study Locations (20 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Arizona State University, Phoenix, Arizona 85004 United States
Phoenix Children's, Phoenix, Arizona 85006 United States
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Children's Hospital Colorado, Aurora, Colorado 80045 United States
Johns Hopkins All Children's Hospital, St. Petersburg, Florida 33701 United States
Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 United States
Boston Children's/Joslin Diabetes Center/Massachusetts General Hospital, Boston, Massachusetts 02215 United States
Colorado Navajo Nation, Shiprock, New Mexico 87420 United States
NYU Langone Health- Brooklyn, Brooklyn, New York 11220 United States
Eligibility Criteria
Inclusion Criteria: Screening will occur to enrich the yield of individuals who are highly predisposed to develop youth-onset T2D and include those with all of the following criteria: * Overweight or obesity with BMI ≥85th percentile * Age 8-13 year for girls, 9-15 year for boys (inclusion younger for girls as puberty tends to start a year earlier in girls) * Tanner Stage 2, 3, or 4 * Elevated HbA1c 5.5-6.4% Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation: * Diabetes based on history, or HbA1c ≥6.5% in the medical record or at screening * Unable/unwilling to provide consent/participate fully * Conditions predisposing to diabetes or altering the trajectory of puberty * Medications affecting glucose dynamics during the screening and enrollment period * Prior treatment with insulin * Use of glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications in the 6 weeks prior to enrollment * Planning treatment with glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications * Use of metformin or any glucose lowering medication for a reason other than treatment of diabetes (e.g., for PCOS) in the 6 weeks prior to enrollment * Planning treatment with metformin or any glucose lowering medication or planning to use such medications for a reason other than treatment of diabetes (e.g., for PCOS) * Known syndromic/monogenic obesity * Blood disorders impacting HbA1c (e.g., anemia, hemoglobin variants) * Major systemic organ disease * History of bariatric surgery or currently planning bariatric surgery * Current pregnancy or currently planning pregnancy * Use of GnRH agonist, estrogen, or testosterone * Individuals who do not speak English or Spanish, given validation of the questionnaires to be utilized
Conditions Dyslipidemia Associated With Type II Dia...
Phase NA
Enrollment 2186
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C). While the benefits of intensive LDL-C lowering are well-established for secondary prevention, evidence remains insufficient for primary prevention in the elderly-specifically for individuals aged 70 years or older with type 2 diabetes who have no prior history of atherosclerotic cardiovascular events. Current guidelines generally recommend moderate-intensity statins for this population based on extrapolated data. However, there is a significant evidence gap regarding whether these older adults, who have not yet experienced a cardiovascular event, derive the same risk-benefit ratio from pharmacological intervention as younger or secondary prevention groups. Furthermore, while ezetimibe (alone or in combination) is an effective alternative for patients with established disease, its efficacy as a primary prevention strategy in older diabetic patients has not been rigorously confirmed through randomized controlled trials (RCTs). Therefore, this study specifically focuses on the primary prevention setting, aiming to determine whether individualized LDL-C target-based therapy is non-inferior to standard moderate-intensity statin therapy in preventing first-time cardiovascular events among older patients with type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Moderate-intensity statin monotherapy — Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years. If the LDL-C is ≥100 mg/dL, the investigator may adjust the statin intensity based on the patient's health status.
  • Drug: Ezetimibe or ezetimibe-statin combination therapy — Treatment will consist of non-pharmacological interventions or marketed medications, including low-dose statins (atorvastatin 5 mg or 10 mg, rosuvastatin 2.5 mg or 5 mg) in combination with ezetimibe 10 mg, or fixed-dose combinations (rosuvamibe 10/2.5 mg, atorvabmibe 10/5 mg, or Rosuzet 10/2.5 mg), for up to 3 years. If the pre-specified LDL-C target is not achieved or drug intolerance occurs, adjustments in dosage or medication will be made.

Primary Outcomes

  • Time from the date of randomization to the first occurrence of a major adverse cardiovascular event (MACE) (0, 3, 12, 24, 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-09
Completion: 2029-12-31
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2186 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sin Gon Kim
Collaborators: Severance Hospital, Hanmi Pharmaceutical Company Limited, Yuhan Corporation
Principal Investigators:
  • Sin Gon Kim, MD (PRINCIPAL_INVESTIGATOR) - Korea University Anam Hospital
  • Bong-Soo Cha, MD (PRINCIPAL_INVESTIGATOR) - Severance Hospital
Contact Information
Study Contact:
Kim
82-2-920-6791
aakmcaaec002@kumc.or.kr
Interventions
  • Drug: Moderate-intensity statin monotherapy — Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years. If the LDL-C is ≥100 mg/dL, the investigator may adjust the statin intensity based on the patient's health status.
  • Drug: Ezetimibe or ezetimibe-statin combination therapy — Treatment will consist of non-pharmacological interventions or marketed medications, including low-dose statins (atorvastatin 5 mg or 10 mg, rosuvastatin 2.5 mg or 5 mg) in combination with ezetimibe 10 mg, or fixed-dose combinations (rosuvamibe 10/2.5 mg, atorvabmibe 10/5 mg, or Rosuzet 10/2.5 mg), for up to 3 years. If the pre-specified LDL-C target is not achieved or drug intolerance occurs, adjustments in dosage or medication will be made.
Study Locations (2 sites)
Korea University ANAM Hospital, Seoul, South Korea
Severance Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Provision of written informed consent to participate in the study by the patient or his/her legally authorized representative after receiving and understanding a detailed explanation of the study * Adults aged 70 years or older * Diagnosed with type 2 diabetes or currently receiving antidiabetic medication, without a history or presence of cardiovascular disease * Either: (1) LDL-C≥100 mg/dL if not receiving lipid-lowering therapy, or (2) currently receiving lipid-lowering therapy (in this case, LDL-C level not restricted) Exclusion Criteria: * Diagnosis of type 1 diabetes * Documented history of atherosclerotic cardiovascular disease at screening, confirmed clinically or by imaging: (1) myocardial infarction; (2) coronary revascularization; (3) currently receiving treatment for acute coronary syndrome; (4) history of ischemic stroke; (5) aortic aneurysm; (6) peripheral arterial disease * Currently undergoing cancer treatment * Severe disease requiring recurrent hospitalization * Frailty (defined as a score ≥3 on the Korean FRAIL questionnaire), or any condition significantly limiting self-care * AST or ALT \>3 × ULN, at screening (however, patients will be eligible if repeat testing at the time of randomization shows levels \<3 × ULN), or liver cirrhosis * Contraindications to study drugs * Pregnant or breastfeeding women
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the efficacy and safety of HRS9531 compared with placebo in participants with type 2 diabetes mellitus not adequately controlled with basal insulin, with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study may include up to 23 visits.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: HRS9531 — HRS9531-low dose
  • Drug: HRS9531 — HRS9531-high dose
  • Drug: Placebo — Placebo

Primary Outcomes

  • Change in HbA1c (from baseline to Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-25
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Hong Chen
+86-0518-82342973
hong.chen@hengrui.com
Linong JI
Perking University Peoples' Hospital
Interventions
  • Drug: HRS9531 — HRS9531-low dose
  • Drug: HRS9531 — HRS9531-high dose
  • Drug: Placebo — Placebo
Study Locations (1 sites)
Perking University Peoples' Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female, able and willing to provide a written informed consent 2. Diagnosed with type 2 diabetes ≥ 90 days; 3. On stable once-daily dose of basal insulin alone or in combination with metformin and/or SGLT2 inhibitor ≥ 90 days; 4. HbA1c was 7.5%\~11.0% (both inclusive); 5. Body Mass Index (BMI) ≥22 kg/m2 at screening. Exclusion Criteria: 1. A history of type 1 diabetes, specific diabetes, or secondary diabetes; 2. Have a history of severe hypoglycemia within t180 days prior to screening; 3. History of acute cardiovascular and cerebrovascular diseases within 180 days prior to screening; 4. Have a history of malignancy within 5 years; 5. Known or suspected allergy or intolerance to the investigational medicinal products or related products; 6. Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 90 days; 7. Any conditions that the Investigator judges might not be suitable to participate in the trial.
Conditions Asthma, Asthma Patients, Asthma Bronchia...
Phase Not Applicable
Enrollment 200
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: BDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg — extrafine SITT

Primary Outcomes

  • Asthma Control Test (6 months)
  • Asthma Control Test 2 (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-04
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Slovenija, d.o.o.
Contact Information
Study Contact:
Mojca Pernek Miložič, MPharm
+38640292828
m.pernek@chiesi.com
Marina Štrucelj, MPharm
0038640177210
m.strucelj@chiesi.com
JASMINA DIMITRIJEVIĆ GOLEŽ, MD
+38631315042
jasmina.golez@gmail.com
AMBULANTA ARIA, specialistična ambulanta za alergijske in pljučne bolezni, d.o.o.
Interventions
  • Drug: BDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg — extrafine SITT
Study Locations (18 sites)
AMBULANTA ARIA, specialistična ambulanta za alergijske in pljučne bolezni, d.o.o., Celje, 3000 Slovenia
Dr. ŠEGOTA - PULMOLOG, specialistične zdravstvene storitve, d.o.o., Celje, 3000 Slovenia
Internistična Ambulanta Za Pljučne in Alergijske Bolezni - Karmen Kramer Vrščaj Dr. Med., Celje, 3000 Slovenia
MEDICOINTERNA, medicinske storitve in svetovanje, d.o.o., Kočevje, 1330 Slovenia
Zdravstveni Dom Koper Casa Della Sanita Capodistria, Koper, 6000 Slovenia
VELOG Zdravstveni center d.o.o., Kranj, Slovenia
ARJANA MAČEK, zdravstvene in druge storitve, d.o.o, Ljubljana, 1000 Slovenia
KAMBIČ - KAFOL, medicinsko svetovanje in storitve, d.o.o., Ljubljana, 1000 Slovenia
MEDI PULMO, interna medicina, d.o.o., Ljubljana, 1000 Slovenia
OBJEM ZDRAVJA zdravstveno svetovalni center d.o.o., Ljubljana, 1000 Slovenia
Eligibility Criteria
INCLUSION CRITERIA: * Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion * Patients ≥ 18 years of age in ambulatory care * Uncontrolled asthma according to the physician's clinical assessment despite the use of: 1. LABA and high dose ICS or 2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months. * Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC : 1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months 2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20) 3. FEV1\<80% at baseline * Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion * Patient provided written, informed consent to study participation EXCLUSION CRITERIA: * Participation in any clinical trial within 30 days prior to enrolment * Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment * Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment. * Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids * Use of continuous oxygen therapy * Any malignant disease in the last 5 years * Tuberculosis (active or anamnestic) * Actual or previous use of biologics for asthma treatment in the past 12 months * All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase Not Applicable
Enrollment 800
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, prospective observational cohort study, in which patients with chronic airway diseases including chronic obstructive pulmonary disease(COPD), asthma, asthma-COPD overlap syndrome (ACOS) will be recruited.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Death (time to death) (upto 20 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2011-09
Completion: 2031-12
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Principal Investigators:
  • Chul-Gyu Yoo, M.D. (STUDY_CHAIR) - Seoul National University Hospital
Contact Information
Study Contact:
Chang-Hoon Lee, M.D.
82-2-2072-4743
kauri670@gmail.com
Ho-Il Yoon, M.D.
dextro70@gmail.com
Seoul National University Bundang Hospital
Ho-Il Yoon, M.D.
Seoul National University Bundang Hospital
Interventions
N/A
Study Locations (3 sites)
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 463-707 South Korea
Seoul National University Hospital, Seoul, 110-744 South Korea
Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, 156-707 South Korea
Eligibility Criteria
COPD Inclusion Criteria: * Postbronchodilator FEV1/FVC \< 0.7 AND chronic respiratory symptom Exclusion Criteria: \- Asthma Inclusion Criteria: * Never smoker or \<5PY of smoking history AND Recurrent episodes of asthma symptoms (wheezing, dyspnea, chest tightness, cough) AND (either Positive BDR OR positive metacholine/mannitol/exercise provocation test) Exclusion Criteria: \- ACOS Inclusion Criteria: * COPD AND Asthma (regardless of smoking status) Exclusion Criteria: \-
Conditions Unipolar Depression, Bipolar Disorder
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Active rTMS over the left DLPFC and over the left DMPFC — Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
  • Device: Active rTMS over the left DLPFC — Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
  • Device: Sham rTMS — Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.

Primary Outcomes

  • Beck Depression Inventory 2 (Before intervention - four weeks after finishing intervention.)
  • Froward digit span (Before intervention - four weeks after finishing intervention.)
  • Language part of Addenbrooke's Cognitive Examination (Before intervention - four weeks after finishing intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-20
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jakub Antczak
Collaborators: Andrzej Frycz Modrzewski Krakow University
Principal Investigators:
  • Wojciech Korzeniowski, MD (PRINCIPAL_INVESTIGATOR) - The Education of Research and Development Center, Babinski Clinical Hospital
Contact Information
Study Contact:
Wojciech Korzeniowski, MD
+48 12 652 45 20
wojciech.korzen@gmail.com
Jakub Antczak, MD
+48 12 400 25 50
jakub.antczak@uj.edu.pl
Wojciech Korzeniowski, MD
+48 12 652 42 00
wojciech.korzen@gmail.com
The Education of Research and Development Center, Babinski Clinical Hospital
Interventions
  • Device: Active rTMS over the left DLPFC and over the left DMPFC — Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
  • Device: Active rTMS over the left DLPFC — Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
  • Device: Sham rTMS — Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
Study Locations (1 sites)
The Education of Research and Development Center, Babinski Clinical Hospital, Krakow, 30393 Poland
Eligibility Criteria
Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Hamilton Depression Rating Scale between between 20 and 35 points at inclusion * The score in the Athens Insomnia Scale eight or more * The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2 * Complaining about problems with memory and concentration timely related with the onset of depression Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion